MLANA and melanoma: Hamid et al. performed a trial involving sixty patients (with high-risk resected melanoma), in which three peptide epitopes (TYR(368–376), MART-1(126–135), and gp100(209–217) were combined with IL-2 and Alum or IL-2 and GM-CSF.